

## Urinary Incontinence Treatment

Date of Origin: 07/2002

Last Review Date: 03/27/2019

Effective Date: 04/01/2019

Dates Reviewed: 01/2004, 02/2005, 01/2006, 02/2007, 03/2008, 03/2009, 02/2011, 02/2012, 02/2013, 02/2014, 10/2015, 03/2016, 06/2017, 08/2018, 03/2019

Developed By: Medical Necessity Criteria Committee

### I. Description

A number of procedures have been investigated for the treatment of urinary incontinence, including pelvic floor muscle exercises, behavioral therapy, sacral nerve stimulation, pelvic floor stimulation, surgery, and radiofrequency energy.

InterStim Continence Control Therapy is **sacral nerve stimulation** that involves the implantation, into the lower back, of electrical leads that are in contact with the sacral nerve root. The wire leads extend through an incision in the abdomen and are connected to an inserted pulse generator to deliver controlled electrical impulses. The physician programs the pulse generator and the individual is able to switch the pulse generator on and off.

Percutaneous tibial nerve stimulation with Urgent® PC by Uroplasty involves the placement of a fine needle electrode into the lower, inner aspect of the leg, near the tibial nerve. The needle electrode is connected to pulse generator that delivers an electrical pulse to the tibial nerve that travels to the sacral plexus. The sacral plexus is responsible for regulating bladder and pelvic floor function. The treatment protocol is for 12 treatments, once a week.

An **artificial urinary sphincter** is a device that involves an inflatable cuff that fits around the urethra. A balloon regulates the pressure of the cuff and a bulb controls inflation and deflation of the cuff. The balloon is surgically placed and the control pump is typically placed in the scrotum for men and the labia for women. The cuff is inflated to prevent incontinence and deflated to allow the patient to urinate.

**Injectable bulking agents** may be effective in decreasing urinary incontinence in men and women with intrinsic sphincter disorder. The bulking agent increases bladder-outlet resistance and/or increases urethral length. The agent is injected into the submucosal tissues of the urethra or bladder neck and/or into the tissues adjacent to the urethra. The injections increase tissue bulk, thereby increasing outlet resistance.

**Posterior tibial nerve stimulation (PTNS)** is a minimally invasive neuromodulation system designed to deliver retrograde electrical stimulation to the sacral nerve plexus through percutaneous of the posterior tibial nerve. PTNS is indicated for treatment of urinary urgency, urinary frequency, and urge incontinence. The specific mechanism of action of neuromodulation is unclear, although theories include improved blood flow and change in neurochemical balance along the neurons.

**Pelvic floor stimulation** involves the electrical stimulation of pelvic floor muscles using either a probe wired to a device for controlling the electrical stimulation, or extracorporeal pulse magnetic innervation.

Innova is a commonly used electrical stimulator that consists of a battery-operated stimulator with a vaginal or rectal electrode. Treatment is performed in the privacy of the patient's home.

Extracorporeal Magnetic Innervation Therapy (ExMI) is a noninvasive conservative treatment for urinary incontinence in adult women. This therapy utilizes a changing magnetic field to induce electrical depolarization of nerves and muscles of the pelvic floor. The use of this device consists of a patient sitting fully clothed in a specialized chair in which the perineum rests on the central axis of a pulsing magnetic field.

**Radiofrequency energy** has been investigated as a technique to shrink and stabilize the endopelvic fascia or the urethra. The SURx Transvaginal System is a radiofrequency device that has been specifically designed as a transvaginal treatment of urinary stress incontinence. The Renessa System is a non-surgical radiofrequency device that uses a balloon catheter system to deliver low temperature radiofrequency energy to the submucosa of the bladder neck and urethra. The controlled heat applied by a radiofrequency device, causes the tissue in the lower urinary tract to become firmer after healing and therefore, increases resistance to involuntary leakage.

## II. Criteria: CWQI HCS-0067A and B

A. Moda Health covers 1 or more of the following:

- a. Implantation of the InterStim (Medtronic), a device for unilateral stimulation of the **sacral nerve** will be covered to plan benefits for the treatment of urge urinary incontinence or symptoms of urge-frequency when **1 or more** of the following criteria are met:
  - i. A **trial** of InterStim device for sacral nerve stimulation is medically indicated when **ALL** of the following are met:
    1. Documentation of 12 months of urge urinary incontinence or symptoms of urge-frequency and the condition has resulted in significant disability (the frequency and/or severity of symptoms are limiting the member's ability to participate in daily activities)
    2. The patient must be refractory to three month trial conventional therapy with **ALL** of the following:
      - a. At least 2 different anti- cholinergic drugs or 1 anti-cholinergic and 1 beta-3 adrenergic receptor agonist

- b. behavioral treatments such as pelvic floor exercise, biofeedback, timed voids, or fluid management
  - ii. **Permanent** placement of the InterStim device is medically indicated when **ALL** of the following criteria are met:
    - 1. Documentation of 12 months of urge urinary incontinence or symptoms of urge-frequency and the condition has resulted in significant disability (the frequency and/or severity of symptoms are limiting the member's ability to participate in daily activities)
    - 2. The Patient must be must be refractory to three month trial conventional therapy with ALL of the following:
      - a. At least 2 different anti- cholinergic drugs or 1 anti-cholinergic and 1 beta-3 adrenergic receptor agonist
      - b. behavioral treatments such as pelvic floor exercise, biofeedback, timed voids, or fluid management
    - 3. A trial of the device has provided at least 50% decrease in incontinence symptoms
- b. Implantation of the InterStim (Medtronic), a device for unilateral stimulation of the **sacral nerve** will be covered to plan benefits for the treatment of non-obstructive urinary retention when **1 or more** of the following criteria are met:
  - i. A **trial** of sacral nerve stimulation is medically indicated when **ALL** of the following are met:
    - 1. Documentation of 12 months of urinary retention and the condition has resulted in significant disability (the frequency and/or severity of symptoms are limiting the member's ability to participate in daily activities)
    - 2. Pharmacotherapies (e.g. alpha blockers and cholinergics, and antibiotics for urinary tract infections) as well as intermittent catheterization have failed or are not well-tolerated
  - ii. **Permanent** placement of Sacral Nerve stimulation is medically indicated when **ALL** of the following criteria are met:
    - 1. Documentation of 12 months of urinary retention and the condition has resulted in significant disability (the frequency and/or severity of symptoms are limiting the member's ability to participate in daily activities)
    - 2. Pharmacotherapies (e.g. alpha blockers and cholinergics, and antibiotics for urinary tract infections) as well as intermittent catheterization have failed or are not well-tolerated
    - 3. A trial of the device has provided at least 50% decrease in residual urine volume
- c. Moda Health considers removal of an InterStim device medically necessary even when the initial implantation of the InterStim was not indicated
- d. The **InterStim** is considered experimental and investigational and is not covered for all other indications because its effectiveness for indications other than the ones listed above has not been established. (Note: bilateral sacral nerve stimulation is considered experimental and investigational for the treatment of urinary incontinence because the effectiveness of this approach has not yet been established).
- e. **Posterior tibial nerve stimulation (PTNS)** is medically necessary when **ALL** of the following criteria are met:

- i. The patient has documentation of urinary urge incontinence, urge frequency, or urge frequency for at least 12 months severe enough that the condition has resulted in a significant disability (the frequency and/or severity of symptoms are limiting the member's ability to participate in daily activities)
  - ii. The patient has failed a three month trial of conservative treatment including pharmacotherapies, Kegel exercises, and behavior modification. (e.g., pelvic floor exercise, biofeedback, timed voids, and fluid management)
  - iii. Percutaneous tibial nerve stimulations considered experimental and investigational when criteria are not met
  - iv. The requested treatment plan is for 12 treatments, once a week.
- f. **Artificial Urinary Sphincters (HCS-0067A)** is covered for the treatment of urinary incontinence due to intrinsic urethral sphincter deficiency with **1 or more of the following**:
  - i. Patient is 6 or more months post-prostatectomy and has not had improvement in the severity of urinary incontinence despite trying pharmacological therapy and behavior modification
  - ii. Patient has epispadias-exstrophy and has not had success with bladder neck reconstruction surgery
  - iii. Patient is a woman with intractable urinary incontinence who has failed behavioral modification, pharmacological therapy, and other surgical treatments
  - iv. Patient is a child with intractable urinary incontinence due to intrinsic urethral sphincter deficiency and has been refractory to behavioral modification or pharmacological therapy and is an unsuitable candidate for other surgical procedures for the correction of the urinary incontinence. Request for indications other than those listed above, is considered experimental and investigational because its effectiveness has not been established.
- g. **Periurethral Injections of Bulking Agents** will be covered to plan limitations when **All** of the following criteria is met:
  - i. The bulking agent is cleared by the FDA for urinary incontinence (e.g., Coaptite [calcium hydroxylapatite], Contigen [glutaraldehyde crossed-linked collagen], Durasphere [carbon-coated spheres/beads], Macroplastique [polydimethylsiloxane], Uryx [ethylene vinyl alcohol copolymer])
  - ii. Patient has urinary incontinence resulting from intrinsic sphincter deficiency that is refractory to 12 months conservative management (e.g. Kegel exercises, biofeedback, electrical stimulation, and/or pharmacotherapies); or
  - iii. The member has stress incontinence for six months and **ALL** of the following:
    - 1. No other causes of stress incontinence (urinary tract infection, etc.)
    - 2. Activities of daily living are limited by the stress incontinence
  - iv. Request for injection of periurethral bulking agents for UI is considered experimental and investigational for neurogenic bladder and all other indications
  - v. Prior to collagen implant therapy, a skin test for collagen sensitivity must be administered and evaluated over a 4 week period. No skin test is required for the carbon-coated beads
  - vi. Request is for 5 injection procedures only.
- h. **Request for continuation of treatment** will be covered for **1 or more** of the following:
  - i. **Posterior tibial nerve stimulation** will be covered when **All** of the following criteria are met:

1. Documentation of improvement of incontinence after 12 treatments
- ii. Periurethral Injections of Bulking Agents will be covered when **All** of the following criteria are met:
  1. Incontinence improves after 3 treatments with bulking agents  
**NOTE:** If incontinence does not improve after 3 treatments with bulking agents, treatment is considered ineffective and further treatment with bulking agents is not considered medically necessary.
- i. The requested procedure does **NOT** include **ALL** of the following as their effectiveness has not been established.
  - i. Radiofrequency energy (SURx, Renessa System, etc.) for the treatment of stress urinary incontinence.
  - ii. The Genityte procedure (laser therapy)
  - iii. Pudendal nerve stimulation
  - iv. Autologous myoblast transplantation
  - v. Autologous muscle-derived cell therapy
  - vi. Collagen porcine dermis mesh
  - vii. Stem cell therapy
  - viii. The extraurethral non-circumferential retropubic adjustable compression devices (ProACT Therapy System, Uromedica, Inc.)
  - ix. Radiofrequency micro-remodeling with SURs System (paraurethral or transvaginal)
  - x. The Neocontrol system, which uses extracorporeal magnetic innervation (ExMI)
  - xi. Additional treatments or systems not listed above that have not been proven to be effective in evidence-based literature.

### III. Information Submitted with the Prior Authorization Request:

1. Chart notes from the treating physician documenting history of incontinence and treatments
2. For review of sacral nerve stimulators and PTNS, 12 months of chart notes from the treating physician are required, documenting that the above criteria are met.

### IV. CPT or HCPC codes covered:

Codes	Description
64561	Percutaneous implantation of neurostimulator electrodes; sacral nerve
64566	Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming
64581	Implantation neurostimulator electrodes; sacral nerve
A4290	Sacral nerve stimulation test lead, each
C1767	GENERATOR, NEUROSTIMULATOR (IMPLANTABLE), NON-RECHARGEABLE
C1778	LEAD, NEUROSTIMULATOR (IMPLANTABLE)
C1815	Prosthesis, urinary sphincter (implantable)
C1883	ADAPTOR/EXTENSION, PACING LEAD OR NEUROSTIMULATOR LEAD (IMPLANTABLE)
C1897	LEAD, NEUROSTIMULATOR TEST KIT (IMPLANTABLE)

L8603	Injectable bulking agent, collagen implant, urinary tract, 2.5 ml syringe, includes shipping and necessary supplies
L8604	Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, urinary tract, 1 ml, includes shipping and necessary supplies
L8606	Injectable bulking agent, synthetic implant, urinary tract, 1 ml syringe, includes shipping and necessary supplies
L8680	IMPLANTABLE NEUROSTIMULATOR ELECTRODE, EACH

## V. CPT or HCPC codes NOT covered:

Codes	Description
53860	Transurethral radiofrequency micro-remodeling of the female bladder neck and proximal urethra for stress urinary incontinence
E0740	Incontinence treatment system, pelvic floor stimulator, monitor, sensor, and/or trainer

## VI. Annual Review History

Review Date	Revisions	Effective Date
02/2013	Annual Review: Added table with review date, revisions, and effective date. Added percutaneous tibial nerve stimulation criteria and description.	03/1/2013
02/2014	Annual Review: No changes	02/25/2014
09/2015	Annual Review: Added ICD-9, ICD-10, HCPC, CPT , Medicare references	09/2
03/2016	Annual Review: Deleted ICD-9 codes – updated Sacral nerve stimulation, updated Medicare references	03/23/2016
06/2017	Annual Review: Updated to new template	07/01/2017
8/2018	Annual Review: Changed percutaneous tibial nerve stimulation to posterior tibial nerve stimulation. Added description of PTNS	08/22/2018
03/2019	Annual Review: Clarified clinical requirements for sacral nerve stimulation, updated HCPC codes	04/01/2019

## VII. References

1. Appell RA, Juma S, Wells WG, et al. Transurethral radiofrequency energy collagen microremodeling for the treatment of female stress urinary incontinence. *Neurourol. Urodyn.* 2006;25(4):331-6.
2. Dmochowski RR, Avon M, Ross J, et al. Transvaginal radio frequency treatment of the endopelvic fascia: a prospective evaluation for the treatment of genuine stress urinary incontinence. *J. Urol.* 2003 Mar;169(3):1028-32.
3. Extracorporeal Magnetic Innervation (ExMI), supplied by the office of Dr H. Tirger, D.O.

4. Gnessin E, Levne PM, Baniel J, Gillon G. Continence and quality of life assessment after artificial urinary sphincter implantation. *Isr Med Assoc J.* 2004 Oct;6(10):592-4.
5. Gousse AE, Madjar S, Lambert MM, Fishman IJ. Artificial urinary sphincter for post-radical prostatectomy urinary incontinence: long-term subjective results. *J Urol.* 2001 Nov; 166(5):1755-8.
6. Herbison GP, Arnold EP. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. *Cochrane Database Sys Rev.* 2009 Apr 15;(2):CD004202
7. Lavelle JP, Teahan S, Kim DY, et al. Medical and minimally invasive treatment of urinary incontinence. *Reviews in Urology.* Spring 1999;1(2):111-120.
8. Magnetic stimulation of the sacral roots for the treatment of stress incontinence: an investigational study and placebo controlled trial, Dept. of Urology, Sankraku Tokyo, Japan. *Journal of Urology-* 2000 Oct.
9. Medtronic, Inc. Sacral nerve stimulation (Interstim Therapy). Updated 2010 1 Jun. Accessed February 17, 2011 at: <http://professional.medtronic.com/therapies/sacral-nerve-stimulation-interstim-therapy/index.htm>
10. Montague DK, Angermeier KW, Paolone DR. Long-term continence and patient satisfaction after artificial sphincter implantation for urinary incontinence after prostatectomy. *J Urol.* 2001 Aug;166(2):547-9.
11. Richardson DA, Miller KL, Siegel ST, et al. Pelvic floor electrical stimulation: a comparison of daily and every-other-day therapy for genuine stress incontinence. *Urology* 1996. Vol 48: 110-118.
12. Siegel SW, Richardson DA, Miller KA, et al. Pelvic floor electrical stimulation for the treatment of urge and mixed urinary incontinence in women. *Urology* 1997. Vol 50: 934-940.
13. The Fundamentals of Pelvic Floor Stimulation. Supplied by EMPI.
14. Centers for Medicare & Medicaid Services; Local Coverage Article: Sacral Nerve Stimulation for Urinary and Fecal Incontinence R3 (A51543); Nordian Healthcare Solutions; effective date 12/01/2011; Revision Effective Date 09/01/2014
15. Centers for Medicare & Medicaid Services; Local Coverage Determination (LCD): Wisconsin Physicians Service Insurance Corporation; Radiofrequency Treatment for Urinary Incontinence (L31615): effective date 06/15/2011; Revision Effective Date 4/1/2015; Updated 3/17/2015
16. Centers for Medicare & Medicaid Services; Local Coverage Article: Sacral Nerve Stimulation for Urinary and Fecal Incontinence R3 (A51543); Nordian Healthcare Solutions; effective date 04/20/2012; Revision Effective Date 09/01/2014; Updated 8/27/2014
17. Centers for Medicare & Medicaid Services; National Coverage Determination (NCD) for Biofeedback Therapy for the Treatment of Urinary Incontinence (30.1.1): effective date 7/01/2001; Implementation Date 7/1/2001
18. Physician Advisors

## Appendix 1 – Applicable ICD-10 diagnosis codes:

Codes	Description
F98.0	Enuresis not due to a substance or known physiological condition
N30.10	Interstitial cystitis (chronic) without hematuria
N30.11	Interstitial cystitis (chronic) with hematuria
N31.2	Flaccid neuropathic bladder, not elsewhere classified
N31.8	Other neuromuscular dysfunction of bladder
N31.9	Neuromuscular dysfunction of bladder, unspecified

N32.81	Overactive bladder
N36.44	Muscular disorders of urethra
N39.3	Stress incontinence (female) (male)
N39.41	Urge incontinence
R32	Unspecified urinary incontinence
R33.9	Retention of urine, unspecified
R35.0	Frequency of micturition
R39.14	Feeling of incomplete bladder emptying
N39.42	Incontinence without sensory awareness
N39.43	Post-void dribbling
N39.45	Continuous leakage
N39.46	Mixed incontinence
N39.490	Overflow incontinence
N39.498	Other specified urinary incontinence
R39.15	Urgency of urination

## Appendix 1 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD):

Jurisdiction(s): 5, 8	NCD/LCD Document (s):
National Coverage Determination (NCD) 30.1.1 Biofeedback Therapy for the Treatment of Urinary Incontinence	<a href="https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=42&amp;ncdver=1&amp;DocID=30.1.1&amp;kq=true&amp;bc=gAAAABAAAAAAAA%3d%3d&amp;">https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=42&amp;ncdver=1&amp;DocID=30.1.1&amp;kq=true&amp;bc=gAAAABAAAAAAAA%3d%3d&amp;</a>
National Coverage Determination (NCD) 230.18 Sacral Nerve Stimulation for Urinary Incontinence	<a href="https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=249&amp;ncdver=1&amp;DocID=230.18&amp;kq=true&amp;bc=gAAAABAAAAAAAA%3d%3d&amp;">https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=249&amp;ncdver=1&amp;DocID=230.18&amp;kq=true&amp;bc=gAAAABAAAAAAAA%3d%3d&amp;</a>
National Coverage Determination (NCD) 230.10 Incontinence Control Devices	<a href="https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=241&amp;ncdver=1&amp;DocID=230.10&amp;kq=true&amp;bc=gAAAABAAAAAAAA%3d%3d&amp;">https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=241&amp;ncdver=1&amp;DocID=230.10&amp;kq=true&amp;bc=gAAAABAAAAAAAA%3d%3d&amp;</a>

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC